Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (3026)	3/29/2008 2:02:14 PM
From: Gary Mohilner	of 3044

Ice, MLNM stopped this trial years ago, some believe they no longer have control of the J591 MAB used in this conjugation. Any idea why this information's being submitted now. It has always been my belief that MLNM gave up on J591 conjugates far to soon, largely I believe because there new CEO at the time wanted to show profits more than new drugs in the pipeline. They had the choice of trying MLN2704 in other protocols that could have proven effective, or conjugating J591 utilizing other linkers and/or effector molecules which IMGN had developed since MLN2704 entered trials. They've done nothing to my knowledge since the trial, but they still hold the rights to the PSMA Target with IMGN. SGEN's two most advanced drugs are drugs that have been abandoned by others. In one case, SGN40, the drug had been abandoned by DNA, sold to SGEN, and after some promising trials has been repurchased by DNA with SGEN getting milestones, royalties and opt in rights at later stages of the trials. While I wouldn't like to see SGEN purchase one of IMGN's conjugates in this way, if someone could gain the rights to the drug or the target, I believe the MAB could be used successfully today. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next